Cochin Hospital, Paris, France
Cochin Hospital, Paris, France.
Clin Med (Lond). 2021 Sep;21(5):e552-e555. doi: 10.7861/clinmed.2020-0666. Epub 2021 Aug 2.
Cancer patients are a highly vulnerable group in the COVID-19 pandemic and it has been necessary for oncology units to adapt to this unexpected situation. We present our management of outpatients with cancer during the pandemic. We applied two major adaptations: extending the intervals between injections for maintenance therapy and protocol adaptation for patients with comorbidities. Between 17 March and 30 April 2020, 406 patients were treated in our outpatients department. Protocols were adapted for 94 (23.1%) patients. Among them, 49% had an extended interval between treatment administrations, 22.3% had modified protocols to reduce toxicity, 20.2% had therapeutic interruptions and 5.3% did not receive their treatment because of a COVID-19 infection. Overall, protocol adaptations concerned more than 20% of the patients. This pandemic was an opportunity for oncologists to re-examine the risk versus benefit balance of administering immunosuppressive treatment and highlighted that oncology daily routine should not be applied automatically.
在 COVID-19 大流行期间,癌症患者是一个高度脆弱的群体,肿瘤科室有必要适应这一意外情况。我们介绍了在大流行期间对门诊癌症患者的管理方法。我们采用了两项主要的调整措施:延长维持治疗的注射间隔和对合并症患者的方案调整。在 2020 年 3 月 17 日至 4 月 30 日期间,我们的门诊部共治疗了 406 名患者。对 94 名(23.1%)患者进行了方案调整。其中,49%的患者治疗间隔延长,22.3%的患者调整了方案以降低毒性,20.2%的患者中断了治疗,5.3%的患者因 COVID-19 感染而未接受治疗。总体而言,超过 20%的患者进行了方案调整。这场大流行是肿瘤学家重新审视给予免疫抑制治疗的风险与获益平衡的机会,并强调肿瘤学的日常工作不应自动进行。